[#item_full_content]WATERTOWN, Mass.–(BUSINESS WIRE)–Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth today backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings. Nido Bio was founded through the 4:59 Initiative at 5AM Ventures. The Series A round was co-led by 5AM Ventures, Abingworth, and Bessemer Venture Partners with participation from Osage